
    
      This is a multi-center, non-blinded, efficacy and tolerability trial in patients with ESRD on
      dialysis three times per week. Approximately 24 patients (approximately twelve diabetic
      patients and approximately twelve non-diabetic patients) in Israel will be initiated on
      KRX-0502 (ferric citrate). The study will consist of a two-week washout period immediately
      followed by a six-week treatment period in. Patients will be initiated on study drug over two
      to three weeks.
    
  